Aptevo expands cancer pipeline with new patents

Aptevo Therapeutics Inc. filed a current report describing a pipeline update.

Rhea-AI Filing Summary

Aptevo Therapeutics Inc. filed a current report describing a pipeline update. On September 4, 2025, the company issued a press release announcing expansion of its anti-cancer pipeline through the filing of two provisional patents for trispecific drug candidates, APVO452 and APVO451. These candidates are being developed for prostate cancer and multiple additional solid tumor types that the company describes as having significant unmet medical needs. The press release with more scientific and development details is included as Exhibit 99.1 to the report.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Aptevo Therapeutics (APVO) disclose in this 8-K filing?

Aptevo Therapeutics disclosed that it issued a press release on September 4, 2025 announcing expansion of its anti-cancer pipeline with two new trispecific candidates and filed the release as Exhibit 99.1.

Which new drug candidates did Aptevo Therapeutics (APVO) highlight?

The company highlighted two trispecific anti-cancer candidates, APVO452 and APVO451, for prostate cancer and multiple additional solid tumor types.

What medical areas are targeted by Aptevo Therapeutics’ new candidates APVO452 and APVO451?

APVO452 and APVO451 are intended for treatment of prostate cancer and multiple additional solid tumor types that are described as having significant unmet needs.

What intellectual property step did Aptevo Therapeutics take for APVO452 and APVO451?

Aptevo Therapeutics filed two provisional patents covering its trispecific candidates APVO452 and APVO451 as part of expanding its anti-cancer pipeline.

Where can investors find more details about Aptevo Therapeutics’ pipeline update?

More details are contained in the company’s press release dated September 4, 2025, which is attached to the report as Exhibit 99.1 and incorporated by reference.

Does this 8-K include financial results or earnings information for Aptevo Therapeutics (APVO)?

No, this report is focused on an other event related to expansion of the anti-cancer pipeline and attachment of a press release, rather than financial or earnings data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/04/2025 - 04:19 PM Learn about SEC filing dates

false000167158400016715842025-09-042025-09-04

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 04, 2025

APTEVO THERAPEUTICS INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-37746	81-1567056
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
2401 4th Avenue Suite 1050
Seattle, Washington				98121
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 838-0500

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		APVO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On September 4, 2025, Aptevo Therapeutics Inc. (the "Company") issued a press release announcing expansion of its anti-cancer pipeline with the filing of two provisional patents for trispecific candidates, APVO452 and APVO451 for prostate cancer and multiple additional solid tumor types with significant unmet needs.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are being filed herewith:

Exhibit No.		Description
99.1		Press release of Aptevo Therapeutics Inc. dated September 4, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			APTEVO THERAPEUTICS INC.
Date:	September 4, 2025	By:	/s/ Marvin L. White
			Marvin L. White President and Chief Executive Officer